Abstract
Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.
| Original language | English |
|---|---|
| Pages (from-to) | 779-791 |
| Number of pages | 13 |
| Journal | Therapeutics and Clinical Risk Management |
| Volume | 11 |
| DOIs | |
| Publication status | Published - 13 May 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Delamanid
- Drug resistance
- MDR-TB
- OPC-67683
- Tuberculosis
Fingerprint
Dive into the research topics of 'The role of delamanid in the treatment of drug-resistant tuberculosis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver